Biotechnology company Biocon has announced that its subsidiary, Biocon Pharma, has
received approval from the US Food and Drug Administration (FDA) to market a generic
medication aimed at treating chronic heart failure. The generic version, Sacubitril/Valsartan
Tablets, will be available in three different strengths: 24 mg/26 mg, 49 mg/51 mg, and 97
mg/103 mg, according to a regulatory filing by the company.
The Sacubitril and Valsartan combination therapy is used to manage chronic heart failure in
adults, helping to reduce the risk of mortality and the likelihood of hospitalization. It is also
approved for treating pediatric patients over the age of one.
This latest approval enhances Biocon’s portfolio of vertically integrated and complex drug
products, furthering the company’s presence in the pharmaceutical market.
Menu
